Document Type : Original Article

Authors

• Aysan Jafari Harandi ^{1, 2}
• Alireza Mirzaee Sedigh ¹
• Mitra Ataei ¹
• Sepideh Bayrami ²
• Emran Esmaeilzadeh ²
• Mohammad Hossein Sanati ¹

¹ Department of Medical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.

² Fetal Health Research Center, Hope Generation Foundation, Tehran, Iran.

Abstract

Background: The mechanisms of the function of interferon beta (IFN-β) and natalizumab (NTZ) in multiple sclerosis (MS) patients have not yet been fully understood. Over the past decades, many studies have been conducted to evaluate gene expression changes especially regulatory non-coding RNAs such as microRNAs (miRNAs) following therapy in MS patients.
Objective: To assess the changes in the expression of miR-20b in MS patients treated with IFN-β or NTZ.
Methods: Sixty patients with relapsing-remitting MS (RRMS) and 30 healthy controls (HCs) were enrolled. The patients were categorized as untreated (N=20), IFN-β-treated (N=20), and NTZtreated (N=20). For the expression analysis, real-time PCR was performed on the whole blood. The bioinformatic tools were applied for signaling pathways enrichment analysis of miR-20b targetome.
Results: The relative expression of miR-20b was significantly downregulated in the untreated patients compared with the HCs (-1.726-fold, p<0.001), while IFN-β-treated and NTZ-treated patients showed no statistical difference compared with the HCs (0.733-fold, p=0.99 for IFN-β and 1.025-fold, p=0.18 for NTZ). This indicates the restoration of miR-20b expression to normal level in the treated patients. Additionally, in silico analysis demonstrated that the Jak–STAT signaling pathway is enriched with miR-20b targets (p<0.0001).
Conclusion: Our findings suggest that the positive effects of IFN-β and NTZ in the RRMS patients could be potentially mediated by returning miR-20b expression to baseline.

Keywords

• Interferon Beta
• Natalizumab
• miR-20b
• Multiple Sclerosis